Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population.

Devon S ConwayCarrie M HershHaleigh C HarrisLe H Hua

Published in: Multiple sclerosis journal - experimental, translational and clinical (2020)

Our results suggest that smoking, depression, and a progressive relapsing multiple sclerosis phenotype are associated with shorter natalizumab treatment durations.

Keyphrases

multiple sclerosis
white matter
depressive symptoms
smoking cessation
stem cells
replacement therapy
rheumatoid arthritis
bone marrow
cell therapy